Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss

doi:10.3748/wjg.v27.i14.1497

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 14

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5451)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

279

WORD

245

HTML

2803

Figures (1-4)

285

Tables (1-3)

228

Sum=3840

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

465

Download

1146

Sum=1611

Apr 14, 2021 (publication date) through Nov 18, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Apr 14, 2021; 27(14): 1497-1506
Published online Apr 14, 2021. doi: 10.3748/wjg.v27.i14.1497

Table 1 Clinical characteristics of the included patients

	Total (n = 83)	Relapser (n = 38)	Non-relapser (n = 45)	P values²
Age at cessation (yr)	32.1 ± 9.5	33.5 ± 9.8	31.0 ± 9.3	0.232
Male, n (%)	56 (67.5)	24 (63.2)	32 (71.1)	0.441
HBsAg < 100 IU/mL, n (%)	19 (22.9)	1 (2.6)	18 (40.0)	< 0.001
Pretreatment HBV DNA (log10 copies/mL)¹	7.17 (6.71-7.68)	7.29 (6.93-7.69)	7.00 (6.10-7.68)	0.123
Total treatment period (mo)¹	49 (36-61)	50 (36-63)	49 (37-61)	0.876
Pretreatment ALT¹	151 (115-287)	149 (118-256)	163 (112 -305)	0.721
Pretreatment AST¹	103 (68-180)	105 (69 -181)	102 (68 -169)	0.927
HBV DNA negativity last time (mo)¹	44 (33-58)	44 (33-60)	44 (34-57)	0.964
Time to HBeAg loss (mo)¹	14 (6-31)	19 (9-33)	12 (6-30)	0.241
Consolidation periods (mo)¹	28 (19-40)	23 (18-38)	30 (21-40)	0.102

¹median (IQR).

²t test, Mann-Whitney U test or χ² test. HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HBsAg: Hepatitis B surface antigen.

Citation: Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506
URL: https://www.wjgnet.com/1007-9327/full/v27/i14/1497.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i14.1497